Notice of Acceptance of CTA Request

RNS Number : 0997O

ValiRx PLC

04 August 2014

 

4 August 2014

ValiRx Plc

("ValiRx" or "the Company")

NOTICE OF ACCEPTANCE OF CTA REQUEST

Re:  Notice of Acceptance of the request to authorise the trial of VAL201 in human patients ("CTA")

ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to report that it has received Notice of Acceptance of its Request for a clinical trial authorisation from the Licensing authority (MHRA) for the trial "A Phase I/II, dose escalation study to assess the safety and tolerability of VAL201 in patients with locally advanced or metastatic prostate cancer and other advanced solid tumours."

The trial will be conducted according to the approved protocol, using the sanctioned material and ratified information, as soon as a favourable opinion on the authorised procedure from the Ethics Committee is obtained.

The Company will  provide further information as the study progresses.

Dr Satu Vainikka, CEO of ValiRx, commented:

"I am thrilled that the VAL201 clinical development has now entered the human patient phase and I am looking forward to receiving information about the compound's performance and behaviour in this critical stage of development. Also, I would like to take this opportunity to thank the project team and its management very much for the effective delivery of this highly complex project.  I look forward to further progress and to updating shareholders accordingly".

- ENDS -

For more information, please contact:

ValiRx plc	Tel: [phone]
Dr Satu Vainikka	www.valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: [phone]
Liam Murray / Avi Robinson
Daniel Stewart & Company Plc (Broker)	Tel: [phone]
David Hart
Peckwater PR	Tel: [phone]
Tarquin Edwards	[e-mail]

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiFinn is the biomarkers and diagnostic development division

2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.

 

END

 

 

MSCQFLFBZVFZBBF